Literature DB >> 34070384

From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy.

Emanuela Di Gregorio1, Gianmaria Miolo2, Asia Saorin1, Agostino Steffan1, Giuseppe Corona1.   

Abstract

Over the last decades, the study of cancer metabolism has returned to the forefront of cancer research and challenged the role of genetics in the understanding of cancer development. One of the major impulses of this new trend came from the discovery of oncometabolites, metabolic intermediates whose abnormal cellular accumulation triggers oncogenic signalling and tumorigenesis. These findings have led to reconsideration and support for the long-forgotten hypothesis of Warburg of altered metabolism as oncogenic driver of cancer and started a novel paradigm whereby mitochondrial metabolites play a pivotal role in malignant transformation. In this review, we describe the evolution of the cancer metabolism research from a historical perspective up to the oncometabolites discovery that spawned the new vision of cancer as a metabolic disease. The oncometabolites' mechanisms of cellular transformation and their contribution to the development of new targeted cancer therapies together with their drawbacks are further reviewed and discussed.

Entities:  

Keywords:  cancer; epigenetics; metabolism; metabolomics; oncometabolites; therapy

Year:  2021        PMID: 34070384     DOI: 10.3390/ijms22115574

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  221 in total

1.  Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.

Authors:  Yang Shen; Yong-Mei Zhu; Xing Fan; Jing-Yi Shi; Qin-Rong Wang; Xiao-Jing Yan; Zhao-Hui Gu; Yan-Yan Wang; Bing Chen; Chun-Lei Jiang; Han Yan; Fei-Fei Chen; Hai-Min Chen; Zhu Chen; Jie Jin; Sai-Juan Chen
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

2.  Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.

Authors:  Anna Tietze; Changho Choi; Bruce Mickey; Elizabeth A Maher; Benedicte Parm Ulhøi; Ryan Sangill; Yasmin Lassen-Ramshad; Slavka Lukacova; Leif Østergaard; Gorm von Oettingen
Journal:  J Neurosurg       Date:  2017-03-03       Impact factor: 5.115

3.  Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.

Authors:  Fumiharu Ohka; Maki Ito; Melissa Ranjit; Takeshi Senga; Ayako Motomura; Kazuya Motomura; Kaori Saito; Keiko Kato; Yukinari Kato; Toshihiko Wakabayashi; Tomoyoshi Soga; Atsushi Natsume
Journal:  Tumour Biol       Date:  2014-03-05

Review 4.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

5.  Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.

Authors:  Stefan Pusch; Sonja Krausert; Viktoria Fischer; Jörg Balss; Martina Ott; Daniel Schrimpf; David Capper; Felix Sahm; Jessica Eisel; Ann-Christin Beck; Manfred Jugold; Viktoria Eichwald; Stefan Kaulfuss; Olaf Panknin; Hartmut Rehwinkel; Katja Zimmermann; Roman C Hillig; Judith Guenther; Luisella Toschi; Roland Neuhaus; Andrea Haegebart; Holger Hess-Stumpp; Markus Bauser; Wolfgang Wick; Andreas Unterberg; Christel Herold-Mende; Michael Platten; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2017-01-25       Impact factor: 15.887

6.  Structural basis of fumarate hydratase deficiency.

Authors:  Sarah Picaud; Kathryn L Kavanagh; Wyatt W Yue; Wen Hwa Lee; Susanne Muller-Knapp; Opher Gileadi; James Sacchettini; Udo Oppermann
Journal:  J Inherit Metab Dis       Date:  2011-03-29       Impact factor: 4.982

7.  Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.

Authors:  Andrew M Brunner; Donna S Neuberg; Seth A Wander; Hossein Sadrzadeh; Karen K Ballen; Philip C Amrein; Eyal Attar; Gabriela S Hobbs; Yi-Bin Chen; Ashley Perry; Christine Connolly; Christelle Joseph; Meghan Burke; Aura Ramos; Ilene Galinsky; Katharine Yen; Hua Yang; Kimberly Straley; Sam Agresta; Sophia Adamia; Darrell R Borger; Anthony Iafrate; Timothy A Graubert; Richard M Stone; Amir T Fathi
Journal:  Cancer       Date:  2018-11-13       Impact factor: 6.921

8.  THE METABOLISM OF TUMORS IN THE BODY.

Authors:  O Warburg; F Wind; E Negelein
Journal:  J Gen Physiol       Date:  1927-03-07       Impact factor: 4.086

9.  5-Azacitidine in patients with IDH1/2-mutant recurrent glioma.

Authors:  Laetitia Federici; Laurent Capelle; Maxime Annereau; Franck Bielle; Christophe Willekens; Caroline Dehais; Florence Laigle-Donadey; Khê Hoang-Xuan; Jean-Yves Delattre; Ahmed Idbaih; Francois Lemare; Stéphane de Botton; Marc Sanson; Mehdi Touat
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 13.029

10.  The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling.

Authors:  Alex Shimura Yamashita; Marina da Costa Rosa; Vittorio Stumpo; Rana Rais; Barbara S Slusher; Gregory J Riggins
Journal:  Neurooncol Adv       Date:  2020-10-29
View more
  2 in total

1.  N6-methyladenosine-related lncRNAs is a potential marker for predicting prognosis and immunotherapy in ovarian cancer.

Authors:  Xin Nie; Jichun Tan
Journal:  Hereditas       Date:  2022-03-18       Impact factor: 3.271

2.  Advances in Cancer Metabolism and Tumour Microenvironment.

Authors:  Karel Smetana; Michal Masařík
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.